Gadgeel SM - Search Results

1

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA. Pietanza MC, et al. Among authors: gadgeel sm. J Thorac Oncol. 2012 Jan;7(1):219-26. doi: 10.1097/JTO.0b013e31822eebf9. J Thorac Oncol. 2012. PMID: 22011666 Free article. Clinical Trial.

2

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. Riely GJ, et al. Lung Cancer. 2007 Feb;55(2):181-5. doi: 10.1016/j.lungcan.2006.10.002. Epub 2006 Nov 7. Lung Cancer. 2007. PMID: 17092603 Clinical Trial.

3

Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Gadgeel SM, et al. J Thorac Oncol. 2007 Apr;2(4):299-305. doi: 10.1097/01.JTO.0000263712.61697.69. J Thorac Oncol. 2007. PMID: 17409801 Free article. Clinical Trial.

4

Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

Wozniak AJ, Belzer K, Heilbrun LK, Kucuk O, Gadgeel S, Kalemkerian GP, Venkatramanamoorthy R, Kraut MJ. Wozniak AJ, et al. Clin Lung Cancer. 2007 Mar;8(5):313-8. doi: 10.3816/CLC.2007.n.010. Clin Lung Cancer. 2007. PMID: 17562230 Clinical Trial.

5

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Heymach JV, et al. J Clin Oncol. 2007 Sep 20;25(27):4270-7. doi: 10.1200/JCO.2006.10.5122. J Clin Oncol. 2007. PMID: 17878479 Clinical Trial.

6

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.

Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Gadgeel SM, et al. Cancer. 2007 Dec 15;110(12):2775-84. doi: 10.1002/cncr.23100. Cancer. 2007. PMID: 17948911 Free article. Retracted.

7

Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.

Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ, Kalemkerian GP. Gadgeel SM, et al. J Thorac Oncol. 2008 Nov;3(11):1293-300. doi: 10.1097/JTO.0b013e31818b194e. J Thorac Oncol. 2008. PMID: 18978565 Free PMC article. Clinical Trial.

8

Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Schneider BJ, Kalemkerian GP, Kraut MJ, Wozniak AJ, Worden FP, Smith DW, Chen W, Gadgeel SM. Schneider BJ, et al. Among authors: gadgeel sm. J Thorac Oncol. 2008 Dec;3(12):1454-9. doi: 10.1097/JTO.0b013e31818de1d2. J Thorac Oncol. 2008. PMID: 19057272 Free PMC article. Clinical Trial.

9

Chronic obstructive lung diseases and risk of non-small cell lung cancer in women.

Schwartz AG, Cote ML, Wenzlaff AS, Van Dyke A, Chen W, Ruckdeschel JC, Gadgeel S, Soubani AO. Schwartz AG, et al. J Thorac Oncol. 2009 Mar;4(3):291-9. doi: 10.1097/JTO.0b013e3181951cd1. J Thorac Oncol. 2009. PMID: 19190518 Free PMC article.

10

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP. Schneider BJ, et al. Among authors: gadgeel sm. Invest New Drugs. 2009 Dec;27(6):571-8. doi: 10.1007/s10637-009-9228-6. Epub 2009 Feb 19. Invest New Drugs. 2009. PMID: 19225720 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page